Oncotarget

Reviews:

Long non-coding RNAs in cutaneous melanoma: clinical perspectives

Eva Hulstaert _, Lieve Brochez, Pieter-Jan Volders, Jo Vandesompele and Pieter Mestdagh

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:43470-43480. https://doi.org/10.18632/oncotarget.16478

Metrics: PDF 937 views  |   HTML 2972 views  |   ?  


Abstract

Eva Hulstaert1, Lieve Brochez1, Pieter-Jan Volders2,3,4, Jo Vandesompele2,3,4 and Pieter Mestdagh2,3,4

1 Department of Dermatology, Ghent University Hospital, Ghent, Belgium

2 Center for Medical Genetics, Ghent University, Ghent, Belgium

3 Cancer Research Institute Ghent, Ghent University, Ghent, Belgium

4 Bioinformatics Institute Ghent, Ghent University, Ghent, Belgium

Correspondence to:

Eva Hulstaert, email:

Keywords: long non-coding RNA, melanoma, biomarkers, cancer therapy

Received: December 15, 2016 Accepted: March 13, 2017 Published: March 22, 2017

Abstract

Metastatic melanoma of the skin has a high mortality despite the recent introduction of targeted therapy and immunotherapy. Long non-coding RNAs (lncRNAs) are defined as transcripts of more than 200 nucleotides in length that lack protein-coding potential. There is growing evidence that lncRNAs play an important role in gene regulation, including oncogenesis. We present 13 lncRNA genes involved in the pathogenesis of cutaneous melanoma through a variety of pathways and molecular interactions. Some of these lncRNAs are possible biomarkers or therapeutic targets for malignant melanoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16478